Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring EGFR G719A/V769M Complex Mutation

Abstract

Francesca Simionato,1 Lorenzo Calvetti,1 Marco Cosci,2 Silvia Scarparo,3 Giuseppe Aprile1 1Department of Oncology, San Bortolo General Hospital, Vicenza, Italy; 2Department of Surgery, San Bortolo General Hospital, Vicenza, Italy; 3Pneumology Unit, San Bortolo General Hospital, Vicenza, ItalyCorrespondence: Francesca Simionato Tel [phone]Email [email protected]: Complex EGFR mutations are rare in non-small cell lung cancer (NSCLC). Limited clinical evidence is available on the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in patients with NSCLC harbouring these uncommon EGFR mutations. Here, we reported the case of a complete metabolic response in a patient with advanced NSCLC carrying the uncommon EGFR G719A/V769M complex mutation treated with the first-line osimertinib.Keywords: non-small cell lung cancer, EGFR complex mutations, osimertinib

Keywords

• non-small cell lung cancer
• egfr complex mutations
• osimertinib